Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study
Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study. Journal Of The American Society Of Nephrology 2020, 31: 435-446. PMID: 31896554, PMCID: PMC7003302, DOI: 10.1681/asn.2019070676.Peer-Reviewed Original ResearchConceptsExtrarenal immune-related adverse eventsImmune-related adverse eventsMulticenter studyRenal prognosisKidney recoveryAdverse eventsMost patientsClinical featuresCombination immune checkpoint inhibitor therapyImmune checkpoint inhibitor initiationImmune checkpoint inhibitor rechallengeImmune checkpoint inhibitor therapyProton pump inhibitor useComplication of immunotherapyLower baseline eGFRNew dialysis requirementWorse renal prognosisCheckpoint inhibitor therapyImmune checkpoint inhibitorsCheckpoint inhibitor initiationBaseline eGFRSubnephrotic proteinuriaCheckpoint inhibitorsDialysis requirementControl patients